The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study Comparative Study
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, is a potential alternative to allopurinol for patients with hyperuricemia and gout. ⋯ Febuxostat, at a daily dose of 80 mg or 120 mg, was more effective than allopurinol at the commonly used fixed daily dose of 300 mg in lowering serum urate. Similar reductions in gout flares and tophus area occurred in all treatment groups.